COVID-19 vaccine-associated dermatomyositis
Marlyn Wu, Maria Karim, Robin Ashinoff
Abstract
Dermatomyositis is a multisystem inflammatory autoimmune myopathy, often characterized by proximal symmetric muscle weakness accompanied with characteristic cutaneous findings.1 Though the precise etiology and pathogenesis of dermatomyositis is not completely understood, environmental factors, drugs, infections, and vaccines have been implicated as potential triggers for the development of this disease. Herein, we report a case of dermatomyositis after the administration of 1 dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine.
Topics & Concepts
DermatomyositisMedicineEtiologyPathogenesisCoronavirus disease 2019 (COVID-19)ImmunologyDermatologyInflammatory myopathyMyopathyDiseaseVirologyPathologyInfectious disease (medical specialty)Inflammatory Myopathies and DermatomyositisSkin Diseases and DiabetesImmunodeficiency and Autoimmune Disorders